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Direct isolation, phenotyping and cloning of low-frequency
antigen-specific cytotoxic T lymphocytes from peripheral blood
P.R. Dunbar*†, G.S. Ogg*†, J. Chen*†, N. Rust†, P. van der Bruggen‡
and V. Cerundolo*†
Cytotoxic T lymphocytes (CTLs) play an important role in
controlling viral infections and certain tumours, but
characterising specific CTL responses has always been
technically limited. Fluorogenic ‘tetramers’ of major
histocompatibility complex (MHC) class I complexes have
been exploited recently to quantify the massive
expansion of specific CTLs in human immunodeficiency
virus (HIV) infection [1]. Here, we use MHC class I
complex tetramers to isolate low-frequency antigen-
specific CTLs directly from human peripheral blood,
allowing the simultaneous phenotypic and functional
characterisation and cloning of these CTLs. We
synthesised a tetramer that specifically stained human
leukocyte antigen (HLA)-A2.1-restricted CTL clones
recognising the influenza matrix protein peptide 58–66,
matrix 58–66 [2]. This tetramer stained between 1 in 1,500
and 1 in 58,000 peripheral blood mononuclear cells
(PBMCs) from HLA-A2.1+ individuals. The surface
phenotype of these cells could be analysed by
fluorescence-activated cell sorting (FACS), and the cells
could be directly sorted into enzyme-linked immunospot
(ELISpot) plates, where they released interferon-g (IFN-g)
within 1 day of antigen exposure. The same population
was cloned by FACS, and the specificity of several
expanded clones was confirmed. Cloning was greatly
simplified and accelerated compared with standard
protocols, and was highly efficient. We also used
tetramer-based sorting to enrich melanoma-specific CTLs
derived from a tumour-infiltrated lymph node. Direct
cloning of specific CTLs from peripheral blood can
provide important information about immunological
memory, CTL responses against tumour antigens and CTL
proliferation and function, and opens up new possibilities
for generating CTLs for adoptive immunotherapy.
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Results and discussion
HLA-A2.1 molecules (A2) were refolded in vitro [1] with
β2 microglobulin and matrix 58–66 (peptide
GILGFVFTL, in single-letter amino-acid code). Com-
plexes were biotinylated and bound to phycoerythrin
(PE)-labelled streptavidin at a 4:1 ratio, to form an
A2–matrix tetramer [1]. This reagent stained CTL clones
specific for matrix 58–66 (Figure 1a) but did not stain
other A2-restricted clones that had different specificities
(data not shown). The A2–matrix tetramer was used to
study matrix-specific CTLs in the PBMCs of individuals
not suffering from known influenza infection to assess
whether tetramers could be used to analyse low-frequency
CTLs, such as memory CTLs, directly ex vivo.
A distinct population of CD8+ cells was repeatably
stained by the A2–matrix tetramer in all PBMC samples
from A2+ individuals (Figure 1b), whereas no cells in up
to 400,000 PBMCs from A2-mismatched donors were
double-stained with equivalent intensity. Staining pat-
terns were unaffected by raising tetramer concentration
beyond that required for maximal clone staining. Fre-
quencies of A2–matrix tetramer+ CD8+ cells in A2+ indi-
viduals (Table 1) were considerably higher than those
previously estimated by limiting dilution analysis
(LDA), but are close to those obtained by ELISpot
analysis for peptide-specific cytokine release [3]. This
result suggests that CD8+ cells stained by the A2–matrix
Figure 1
FACS profiles of A2–matrix tetramer-stained cells. (a) A CTL clone
recognising matrix 58–66 and (b) PBMCs from a healthy HLA-A2.1+
individual were double-stained with PE-labelled A2–matrix tetramer
and Tricolor–anti-CD8 (Caltag) for 15 min each, then washed
extensively in FACS buffer (1% foetal calf serum in PBS) before
analysis on a FACSort (Becton Dickinson). Cells shown are small
lymphocytes gated by forward and side scatter profile.
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tetramer include a proportion of cells that would fail to
register in LDA because of their limited proliferative
potential [3].
To determine the phenotype of the A2–matrix tetramer+
CD8+ cells, we used triple-staining to characterise
surface markers, and developed novel FACS-based
assays to test the effector function and proliferative
potential of these cells. Such coordinated assessment of
the phenotype and function of low-frequency CTLs
from peripheral blood has not previously been possible
with other techniques.
A large number of PBMCs were obtained from one A2+
individual (termed H3). The frequency of A2–matrix
tetramer+ CD8+ cells in this sample was consistently about
1 in 3,700 PBMCs and 1 in 2,500 small lymphocytes
(Figure 1b). These cells were CD45RO+ and CD45RA–,
consistent with them having previously been exposed to
antigen. At least 74% of the A2–matrix tetramer+ CD8+
cells in the PBMCs of H3 expressed the Vβ17 T-cell
receptor (TCR) chain, compared with 4% of the
A2–matrix tetramer– CD8+ PBMCs (data not shown).
These data confirm the bias towards the use of the Vβ17
chain that had been observed previously in cloned CTLs
recognising matrix 58–66 [4]. Only 36% of A2–matrix
tetramer+ CD8+ cells in the PBMCs of H3 expressed
CD28, compared with 75% of A2–matrix tetramer– CD8+
cells (data not shown). This finding is consistent with the
majority of A2–matrix tetramer+ CD8+ cells having a
reduced proliferative potential due to a longer replicative
history, as has been reported previously for other CD28–
CD8+ cells [5].
The specificity and activation of A2–matrix tetramer+
CD8+ PBMCs was studied by the ELISpot assay, which
produces ‘spots’ of colour wherever individual CTLs
release IFN-γ. In control experiments, a CTL clone spe-
cific for matrix 58–66 was stained with the A2–matrix
tetramer and anti-CD8; 100 A2–matrix tetramer+ CD8+
cells were then sorted directly into duplicate wells of an
ELISpot plate containing HLA-A2.1+ target cells (T2)
that had been pre-pulsed with either matrix 58–66 or the
negative-control peptide melan-A 26–35 (EAAGIG-
ILTV) [6]. No IFN-γ was released from the A2–matrix
tetramer+ CD8+ clones exposed to control peptide
(Figure 2a), indicating that tetramer staining does not by
itself activate clones to produce cytokine. IFN-γ was
released from clones exposed to matrix 58–66, however,
with approximately one IFN-γ spot produced per CTL
within 1 day, indicating that all the cells had been acti-
vated by recognition of their cognate peptide. We then
stained PBMCs from H3, and sets of 15 cells were sorted
into duplicate ELISpot wells and incubated with
peptide-pulsed targets for either one or two days. IFN-γ
release was observed only when A2–matrix tetramer+
CD8+ PBMCs were exposed to targets pulsed with
matrix 58–66 (Figure 2b); these cells did not recognise
targets pulsed with the negative-control peptide MAGE-
3 271–279 (FLWGPRALV) [7]. A2–matrix tetramer–
CD8+ PBMCs did not produce IFN-γ in response to
either peptide. Results were essentially the same after
either 1 or 2 days incubation, although the IFN-γ spots
were less intense in colour at the earlier time point. The
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Table 1
Frequencies of A2–matrix tetramer+ CD8+ cells per total
PBMCs in HLA-A2.1+ individuals H1–H11.
Individual Frequency
H1 1 in 1,500
H2 1 in 3,100
H3 1 in 3,700
H4 1 in 10,900
H5 1 in 12,900
H6 1 in 19,100
H7 1 in 20,100
H8 1 in 22,000
H9 1 in 34,000
H10 1 in 40,300
H11 1 in 58,000
Figure 2
ELISpot analysis of A2–matrix tetramer-stained cells. (a) A CTL clone
recognising matrix 58–66 and (b) PBMCs from a healthy HLA-A2.1+
individual were double-stained and sorted directly into a 96-well
ELISpot plate (MAIP S45; Millipore) using a FACS Vantage (Becton
Dickinson) running CellQuest and CloneCyt software. Each well
contained 100 µl of RPMI 1640 medium with 5% human serum and
5,000 HLA-A2.1+ target cells (T2) that had been pre-incubated
overnight in serum-free medium with 10 µM of either matrix 58—66 or
the negative-control peptides melan-A 26—35 and MAGE-3 271—279,
then washed before plating. Sorted A2–matrix tetramer+ CD8+ or
A2–matrix tetramer– CD8+ cells were cultured with targets for 1 or
2 days before developing the ELISpot for IFN-γ as described by the
manufacturer (Mabtech). (b) Results after 2 days incubation.
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number of spots formed was similar to the number of
PBMCs placed in the wells, suggesting that the majority
of A2–matrix tetramer+ CD8+ PBMCs were capable of
responding specifically to antigen within 1 day. These
data support the concept that most circulating influenza-
specific memory CD8+ cells are capable of rapid effector
function when triggered by exposure to cognate peptide
in the absence of cytokine [3], even when the peptide is
presented by cells that are not professional antigen-pre-
senting cells.
To further confirm the specificity of A2–matrix tetramer+
CD8+ PBMCs, and to study their proliferative potential,
single cells from the PBMCs of H3 were sorted directly
into cloning wells. Out of 60 wells seeded with A2–matrix
tetramer+ CD8+ cells, 15 contained proliferating blasts
after 2 weeks, and the four most proliferative clones were
tested in duplicate ELISpot assay for antigen-specificity,
along with one proliferating A2–matrix tetramer– CD8+
clone. As shown in Figure 3a, all four A2–matrix
tetramer+ CD8+ clones specifically synthesised IFN-γ
when exposed to targets pulsed with matrix 58–66, but
not when exposed to targets pulsed with control peptide,
whereas the A2–matrix tetramer– CD8+ clone failed to
respond to the same target cells. One expanded
A2–matrix tetramer+ CD8+ clone was also tested in a
chromium-release assay, where it specifically lysed
targets pulsed with matrix 58–66 (Figure 3b).
Finally, to demonstrate the potential of tetramer-based
FACS protocols for the analysis of tumour-specific CTL
responses, we synthesised an A2 tetramer with the melan-
A 26–35 peptide, which derives from a common
melanoma antigen [6]. This tetramer was used to stain
and sort a polyclonal CTL line, MM7, which had been
generated from an A2+ melanoma-infiltrated lymph node.
MM7 contained only a small proportion of cells (6%) that
could be double-stained with A2–melan-A tetramer and
anti-CD8. MM7 specifically killed A2-matched targets
pulsed with melan-A 26–35, but it also poorly killed two
A2-matched melanoma lines expressing melan-A, and
demonstrated small background killing of target cells
pulsed with a negative-control peptide (Figure 4a). An
aliquot of MM7 was then enriched for A2–melan-A
tetramer+ CD8+ cells by FACS, to form the line MM7-E,
which contained 42% A2–melan-A tetramer+ CD8+ cells.
MM7-E killed the melanoma lines and targets pulsed
with melan-A 26–35 much more efficiently than MM7,
with no background killing (Figure 4b). Hence, specific
cytotoxicity correlates entirely with the percentage of
tetramer staining, indicating that tetramer staining fol-
lowed by FACS can be used to generate highly effective
tumouricidal CTL lines.
In conclusion, we have demonstrated that tetrameric
MHC class I complexes can be used to identify and char-
acterise low-frequency CTLs of defined specificity
directly ex vivo. In peripheral blood, CTLs specific for
the influenza matrix 58–66 epitope were more frequent
than recognised previously and were rapidly reactive to
antigen, although only a minority had significant prolifer-
ative potential. Heterogeneity of CD28 expression in
this CTL population suggests that functional differ-
ences, such as the ability to generate large numbers of
progeny by clonal expansion, may co-segregate with
surface phenotype.
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Figure 3
Cloning of specific CTLs directly from PBMCs
using A2–matrix tetramer. PBMCs were
stained with A2—matrix tetramer and anti-CD8,
and sorted as for Figure 2 as single cells
directly into cloning wells containing 100,000
irradiated mixed PBMCs from three donors, in
100 µl Iscove’s medium, supplemented with
5% human serum and 5 µg/ml
phytohaemagglutinin. Clones were fed with 
IL-2 to 15 U/ml and Lymphocult T (Biotest) to
10% on day 4, and with IL-2 to 50 U/ml on
day 10 and every third day subsequently.
(a) After 14 days culture, ELISpot analysis
was performed as for Figure 2, using 10% of
each clone per well. (b) One expanded clone
was subsequently tested in a standard 4 h
chromium-release assay for its ability to lyse
HLA-A2.1+ target cells (the B-cell
lymphoblastoid line .45) pulsed with either
matrix 58–66 or the negative-control peptide
melan-A 26—35. Percentage specific lysis
was calculated by the formula: 100× (specific
release — spontaneous release)/(maximal
release — spontaneous release).
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We have also demonstrated that antigen-specific CTLs
can be cloned directly from PBMCs using tetramers. In
marked contrast to traditional methods, only a small
number of clones need to be seeded and screening of the
clones requires minimal effort. This technique will accel-
erate advances in our understanding of CTLs and might
also offer new opportunities in adoptive immunotherapy,
particularly in rapidly progressive conditions, such as
metastatic malignant melanoma, where the time available
for intervention is limited.
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Figure 4
Sorting of melanoma-specific CTLs using
A2–melan-A tetramer. Polyclonal CTL line
MM7 was generated from an HLA-A2.1+
melanoma-infiltrated lymph node by repeated
rounds of stimulation with melan-A 26–35
peptide and tissue culture in the presence of
IL-2. MM7 was stained with A2–melan-A
tetramer and anti-CD8, as described for
Figure 1, and shown to be 6% double-
positive. Double-positive cells were enriched
in an aliquot of MM7 by FACSorting to form
the polyclonal CTL line MM7-E, which was
42% double-positive. Both CTL lines were
simultaneously tested in a standard 4 h
chromium-release assay for their ability to lyse
HLA-A2.1+ target cells. Targets were T2 cells,
pulsed with either melan-A 26–35 or matrix
58–66 as the negative control, and the HLA-
A2.1+ melanoma cell lines SK-mel-29 and
ME275, both of which express melan-A.
Percentage specific lysis was calculated as
for Figure 3b.
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